The board of directors of Dicot Pharma has resolved on a rights issue of approximately SEK 122.6 million
Uppsala, Sweden, August 7, 2024. The Board of Directors of Dicot Pharma AB ("Dicot" or the "Company") announced on June 30, 2024, its intention to resolve on a rights issue, consisting of shares and warrants ("Units"), of approximately SEK 125 million. With the support of authorization from the Extraordinary General Meeting on August 1, 2024, the Board of Directors of Dicot has today resolved on an issue of Units of approximately SEK 122.6 million with preferential rights for the Company's existing shareholders (the "Rights Issue"). The subscription price has been set at SEK 1.20 per Unit,